EAU 2017 - Prostate Cancer - Results from #63

Viewing 64-83 of 87 articles

EAU 2017: Observation or active surveillance or curative treatment: What do PIVOT data tell us?

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Imaging-based biomarkers: mpMRI

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Tissue-based biomarkers: CCP

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Blood and urine-based biomarkers

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: The role of miRNA in oncogenesis and progression

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Dietary and lifestyle factors

EAU 2017: Special session of the Prostate Cancer Prevention Group: PLCO

EAU 2017: Special session of the Prostate Cancer Prevention Group: ERSPC

EAU 2017: Special session of the Prostate Cancer Prevention Group: ProtecT

EAU 2017: 4th ESO Prostate Cancer Observatory: The Urologist’s Perspective on Active Surveillance

EAU 2017: 4th ESO Prostate Cancer Observatory: The Imaging Specialist’s Perspective on MRI

EAU 2017: 4th ESO Prostate Cancer Observatory: The Pathologist’s Perspective

EAU 2017: 4th ESO Prostate Cancer Observatory: The Radiation Oncologist’s Perspective

EAU 2017: 4th ESO Prostate Cancer Observatory: The Medical Oncologist’s Perspective

EAU 2017: 4th ESO Prostate Cancer Observatory: The Imaging Specialist’s Perspective on PSMA

EAU 2017: What is the optimal post-operative management of men with lymph node recurrent prostate cancer after salvage lymph node dissection? Results from a large, multi-institutional series

Cytoreductive Radical Prostatectomy cRP in men with hormone-naive, metastatic prostate cancer (mPCA) | EAU 2017:

EAU 2017: Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP)

EAU 2017: Predictors of early cancer specific and other cause mortality in high risk prostate cancer patients after radical prostatectomy: Results from a large, multi-institutional analysis

EAU 2017: Does nadir testosterone at the end of long term androgen deprivation therapy predict outcomes in high risk prostate cancer? Data from a phase III trial

1
2
3
4
5